Want to see CCCC full AI Analyst Report?
Top Page
C4 Therapeutics
(NASDAQ:CCCC)
Select Model
Select Model
Rating:59Neutral
Price Target:
$4.50
▲(54.11% Upside)
Action:Reiterated
Date:06/25/26
The score is held back primarily by weak financial performance (deep losses and significant cash burn) and limited valuation support (negative P/E). Offsetting these are strong technical uptrend signals and positive corporate developments, particularly the Roche collaboration and continued clinical progress with an indicated runway through 2028.
Positive Factors
Strategic Roche Collaboration
The broadened Roche deal provides meaningful non-dilutive funding, tiered royalties and leverages Roche for development, regulatory and commercialization. This durable partnership reduces execution risk, validates TORPEDO platform and enhances long-term commercial optionality for DAC modalities.
Negative Factors
High Cash Burn
Sustained negative operating and free cash flow near -$95M TTM implies ongoing heavy cash consumption to fund R&D. Over a multi-quarter horizon this elevates dilution or milestone-dependency risk if partnerships or milestone receipts are delayed, pressuring capital structure and strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic Roche Collaboration
The broadened Roche deal provides meaningful non-dilutive funding, tiered royalties and leverages Roche for development, regulatory and commercialization. This durable partnership reduces execution risk, validates TORPEDO platform and enhances long-term commercial optionality for DAC modalities.
Read all positive factors
C4 Therapeutics (CCCC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$471.02M
Dividend YieldN/A
Average Volume (3M)2.77M
Price to Earnings (P/E)―
Beta (1Y)2.39
Revenue Growth-12.37%
EPS Growth19.59%
CountryUS
Employees110
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.19
Shares Outstanding110,567,220
10 Day Avg. Volume2,168,734
30 Day Avg. Volume2,765,733
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.62
Price to Sales (P/S)4.40
P/FCF Ratio-1.59
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue9.23
Enterprise Value/Gross Profit9.74
Enterprise Value/Ebitda-3.21
Forecast
1Y Price Target
$10.33Price Target Upside253.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$22.84M
C4 Therapeutics Business Overview & Revenue Model
Company Description
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions incl...
How the Company Makes Money
C4 Therapeutics makes money primarily through (1) collaboration and licensing arrangements and (2) to a lesser extent, other operating income; as a clinical-stage company, it has historically not relied on product sales and its ability to generate...
C4 Therapeutics Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
63
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.86M | 35.95M | 35.58M | 20.76M | 31.10M | 45.78M |
| Gross Profit | 33.06M | 27.97M | 35.58M | 13.02M | 31.10M | 45.78M |
| EBITDA | -100.38M | -102.91M | -103.37M | -122.10M | -124.28M | -80.25M |
| Net Income | -103.80M | -104.99M | -105.32M | -132.49M | -128.18M | -83.89M |
Balance Sheet | ||||||
| Total Assets | 328.86M | 359.07M | 349.60M | 376.45M | 430.84M | 506.76M |
| Cash, Cash Equivalents and Short-Term Investments | 235.67M | 248.54M | 244.90M | 253.68M | 276.15M | 309.28M |
| Total Debt | 58.45M | 59.98M | 65.76M | 70.98M | 87.15M | 42.88M |
| Total Liabilities | 94.61M | 102.49M | 133.62M | 130.34M | 141.61M | 117.16M |
| Stockholders Equity | 234.25M | 256.59M | 215.99M | 246.11M | 289.23M | 389.61M |
Cash Flow | ||||||
| Free Cash Flow | -96.02M | -99.30M | -65.34M | -108.55M | -111.44M | -88.24M |
| Operating Cash Flow | -95.35M | -98.69M | -65.16M | -106.84M | -105.94M | -86.97M |
| Investing Cash Flow | -21.57M | -8.60M | -51.27M | 158.35M | 58.42M | -189.34M |
| Financing Cash Flow | 126.91M | 126.40M | 45.34M | 45.49M | 1.15M | 171.40M |
C4 Therapeutics Technical Analysis
Positive
2.92
Price Trends
3.51
Positive
3.02
Positive
2.70
Positive
Market Momentum
0.21
Negative
61.13
Neutral
77.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCCC, the sentiment is Positive. The current price of 2.92 is below the 20-day moving average (MA) of 4.04, below the 50-day MA of 3.51, and above the 200-day MA of 2.70, indicating a bullish trend. The MACD of 0.21 indicates Negative momentum. The RSI at 61.13 is Neutral, neither overbought nor oversold. The STOCH value of 77.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CCCC.
C4 Therapeutics Risk Analysis
C4 Therapeutics disclosed 73 risk factors in its most recent earnings report. C4 Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
C4 Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $471.02M | -3.58 | -50.68% | ― | -12.37% | 19.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.50B | ― | -47.12% | ― | ― | 41.60% | |
49 Neutral | $291.77M | -4.34 | -96.80% | ― | ― | -1.48% | |
46 Neutral | $68.56M | -1.37 | -127.30% | ― | ― | 49.74% | |
41 Neutral | $29.54M | -1.20 | 241.39% | ― | ― | 38.95% |
* Healthcare Sector Average
CCCC
C4 Therapeutics
4.26
2.83
197.90%
SLS
SELLAS Life Sciences Group
12.39
10.20
465.75%
MCRB
Seres Therapeutics
7.08
-4.03
-36.27%
ELDN
Eledon Pharmaceuticals
3.78
1.07
39.48%
TVGN
Tevogen Bio Holdings
7.00
-55.50
-88.80%
ACTU
Actuate Therapeutics, Inc.
1.68
-4.43
-72.50%
C4 Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
C4 Therapeutics Shareholders Back Directors, Pay and Auditors
Positive
Jun 24, 2026
On June 24, 2026, C4 Therapeutics, Inc. held its Annual Meeting of Stockholders, at which shareholders elected Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar as Class III directors to serve until the 2029 annual meeting. Stockholders ...
Business Operations and Strategy
C4 Therapeutics Highlights Cemsidomide Strategy and Trial Progress
Positive
Jun 11, 2026
On June 11, 2026, C4 Therapeutics posted a new corporate presentation detailing its strategic focus on best-in-class and first-in-class targeted protein degraders, highlighting cemsidomide for multiple myeloma and its discovery work in inflammatio...
Business Operations and StrategyExecutive/Board Changes
C4 Therapeutics Realigns Finance Leadership After Officer Departure
Neutral
May 15, 2026
C4 Therapeutics, Inc. announced that on May 12, 2026, it decided Chief Accounting Officer Mark Mossler will leave his role effective May 15, 2026, with the company stating his departure is not related to any disagreement over financial reporting, ...
Business Operations and StrategyFinancial Disclosures
C4 Therapeutics Reports Q1 Results and Clinical Advancements
Positive
May 12, 2026
On May 12, 2026, C4 Therapeutics reported first-quarter 2026 results and highlighted clinical progress, including dosing first patients in its Phase 2 MOMENTUM trial and a Phase 1b trial combining cemsidomide, dexamethasone and elranatamab for mul...
Business Operations and StrategyPrivate Placements and Financing
C4 Therapeutics Expands Roche Collaboration with New DAC Deal
Positive
Apr 9, 2026
On April 8, 2026, C4 Therapeutics entered a new research collaboration and license agreement with Roche to discover, develop and commercialize degrader-antibody conjugates for two undisclosed oncology targets, with an option for a third. Roche wil...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.